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Cytokine resistance is a well-established feature of melanoma cell progression and represents also a major ob-
stacle in immunotherapy of patients with metastatic melanoma. To check whether suppressors of cytokine sig-
nalling (SOCS) play a role in cytokine resistance and tumor progression of melanoma, we investigated the
expression and regulation of SOCS-1, an established negative regulator of interleukin-6 (IL-6) and interferon (IFN)
signalling. In vitro SOCS-1 transcripts were detectable by RT-PCR in 8 out of 8 human melanoma cell lines derived
from different tumor stages. Normal human melanocytes also expressed SOCS-1 mRNA in the presence or absence
of artiﬁcial growth factors. Both IL-6 and a-IFN induced rapid and transient SOCS-1 mRNA expression in WM35 and
WM9 melanoma cells. At the protein level, SOCS-1 was undetectable in normal human melanocytes whereas
uniformly expressed in all tested melanoma cell lines. The aberrant SOCS-1 protein expression in melanoma cells
was recapitalized in situ as shown by immunohistochemical analysis. SOCS-1 immunoreactivity was closely re-
lated to tumor invasion (Clark level), tumor thickness according to Breslow, and stage of the disease. In contrast,
melanocytes in normal skin or melanocytic nevi lacked SOCS-1 protein expression. Our ﬁndings show that me-
lanoma cells express a member of the SOCS family, SOCS-1, in vitro and in situ. SOCS-1 is a progression marker of
human melanoma and may downregulate biological responses by endogenous and/or therapeutically administered
cytokines.
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Suppressers of cytokine signalling (SOCS) constitute a
newly identified family of proteins which negatively regulate
cytokine signal transduction (Krebs and Hilton, 2000;
Yasukawa et al, 2000). The first member of this family,
SOCS-1 (also called JAB or SSI-1), was cloned in 1997
(Endo et al, 1997; Naka et al, 1997; Starr et al, 1997). At
present, the SOCS family consists of 8 structurally related
members, SOCS-1–7, and CIS (cytokine-inducible SH2-
containing protein), which share a central Src-homology 2
(SH2) domain and a conserved C-terminal domain termed
the SOCS box. Expression of SOCS-1–3 and CIS has been
found to be heterogeneously induced by a variety of
cytokines and growth factors such as interleukin (IL)-1, -2,
-3, -4, -6, -7, -12, interferons (IFN), tumor necrosis factor-a
(TNF-a), erythropoietin, and oncostatin-M (OSM) (Starr et al,
1997; Magrangeas et al, 2001). When overexpressed,
SOCS proteins inhibit cytokine signalling by various
cytokines and growth factors suggesting that SOCS func-
tion as mediators of a classical negative feedback loop.
Whereas the precise role of some members of the SOCS
family remains poorly understood, it is well established that
SOCS-1 and -3 negatively regulate cytokine receptor sig-
nalling by inhibition of the Janus kinases (JAK) (Narazaki
et al, 1998; Nicholson et al, 1999). Accordingly, inhibition of
JAK tyrosine kinase (JAK1, JAK2, and Tyk2) activity by
SOCS-1 or -3 leads to reduced activation of distinct mem-
bers of the signal transducer and activator of transcription
(STAT) family, resulting in suppression of the biological
effects of IL-6 and IFN (Sakamoto et al, 1998; Song and
Shuai, 1998; Novak et al, 1999; Iwamoto et al, 2000).
Suppression of biological responses to distinct pro-
inflammatory cytokines is a feature of many transformed
cell types including melanocytes (Kerbel, 1993). This phe-
nomenon was named multi-cytokine resistance and has
been reported for IL-6 (Lu and Kerbel, 1993), transforming
growth factor-b1 (Rodeck et al, 1994), OSM (Lu et al, 1993),
IFN (Wong et al, 1997), IL-1, and TNF-a (Lu et al, 1992). In
case of IL-6, it was shown that treatment of melanoma cell
lines established from early primary lesions are growth-
inhibited by IL-6 in the G1 phase, whereas a high proportion
of cell lines derived from advanced primary tumors or metas-
tases are IL-6 resistant (Lu et al, 1992; Lu and Kerbel, 1993).
This phenomenon was not due to reduced expression of the
IL-6 receptor (Lu and Kerbel, 1993), suggesting deviations
downstream, i.e., within the IL-6 signal transduction
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pathway or in the IL-6-regulated cell cycle events as the
molecular cause for IL-6 resistance. We recently reported
that IL-6-resistant WM9 melanoma cells display complex
defects in activation of STAT3 (Bo¨hm et al, 2001). IL-6-re-
sistant WM9 melanoma cells exhibit impaired tyrosine-705
phosphorylation, reduced DNA binding, and an altered
subcellular distribution of STAT3 in response to IL-6, com-
pared with IL-6-sensitive WM35 cells. The IL-6-resistant
melanoma cells lack inhibition of cyclin-dependent kinase-2
and hypophosphorylation of retinoblastoma protein, two
important regulators of G1/S transition (Florenes et al, 1999;
Bo¨hm et al, 2001). In addition, deviations in IL-6-mediated
regulation of mitogen-activated protein kinase kinase-1 ac-
tivity could be identified in WM9 melanoma cells (Bo¨hm et al,
2001).
Cytokine resistance is also of major clinical importance
for immunotherapy of melanoma. In contrast to a number of
other malignancies, it is well known that immunotherapy
with IFNs alone or in combination with anticancer drugs has
little effect in patients with advanced melanoma. Accord-
ingly, the response rate of patients with metastatic me-
lanoma being treated with recombinant human a-IFN is
15% at best (Legha, 1997; Eggermont, 2001). The reason
for this is poorly understood. Therefore, studies aiming at
identifying molecular mechanisms that determine cytokine
resistance remain a major goal in order to optimize immuno-
therapy of patients with advanced melanoma.
In this paper we addressed whether SOCS-1, a known
inhibitor of IL-6- and IFN-mediated biological responses,
is expressed in melanoma. We demonstrate that in vitro
SOCS-1 transcripts are constitutively present in normal and
transformed human melanocytes, whereas SOCS-1 protein
is detectable only in melanoma cells. Although there was no
correlation between SOCS-1 expression and IL-6 sensitivity
in the tested cell lines, SOCS-1 turned out to be expressed
as a matter of melanoma progression in situ.
Results
Detection of SOCS-1 transcripts in normal and trans-
formed human melanocytes in vitro To check if SOCS-1
expression correlates with tumor progression and/or plays a
role for IL-6 resistance of melanoma cells, we examined
cultured normal human melanocytes (NHM) as well as a
panel of human melanoma cell lines established from dif-
ferent stages of disease progression. The latter included
WM35 cells established from the radial growth phase of a
primary melanoma, WM902B cells derived from the vertical
growth phase of a primary tumor, IPC298, A376 and G361
cells (all derived from advanced solid primary tumors), SK-
Mel-30, IGR-37, and WM9 cells (all from melanoma
metastases). WM35, WM902B, and A375 melanoma cells
respond to IL-6 with growth inhibition (Lu and Kerbel, 1993;
Kortylewski et al, 1999; Bo¨hm et al, 2001) whereas WM9
cells are insensitive toward IL-6 and produce this cytokine
in an autocrine fashion (Lu and Kerbel, 1993; Bo¨hm et al,
2001).
RT-PCR analysis demonstrated that all tested melanoma
cell lines express SOCS-1 transcripts regardless of their
state of IL-6 sensitivity (Fig 1). The size of the amplification
product in melanoma cells was identical with that of a-IFN-
stimulated human PBL which served as a positive control
(Brender et al, 2001) (Fig 1). The identity of the 201 bp am-
plification product in one representative melanoma cell line
(WM902B) was confirmed by sequencing and found to be
identical with the mRNA sequence of SOCS-1 as deposited
in the National Center for Biotechnology Information data-
base (data not shown). Expression of SOCS-1 transcripts
was also detectable in NHM maintained in routine culture
medium containing artificial growth supplements such as
phorbol ester (data not shown) as well as in medium sup-
plemented with natural melanocyte peptide growth factors,
e.g., HGF and ET-1 (Bo¨hm et al, 1995) (Fig 1). These data
demonstrate that normal and transformed human me-
lanocytes in vitro express SOCS-1 transcripts in a consti-
tutive manner.
IL-6 and a-IFN upregulate SOCS-1 mRNA expression in
melanoma cells in vitro We next wondered if exogenous
IL-6 or a-IFN can regulate SOCS-1 expression in human
melanoma cells. Two representative melanoma cell lines
with differential IL-6 sensitivity, WM35 (IL-6 sensitive), and
WM9 (IL-6 resistant), were chosen for these experiments.
Both cell lines responded to IL-6 and a-IFN with marked
increase in the relative amounts of SOCS-1 mRNA as de-
termined by quantitative real-time PCR (Fig 2A and B). The
time kinetics of SOCS-1 mRNA expression differed between
IL-6 and a-IFN and was also heterogeneous between
WM35 and WM9 melanoma cells. In WM35 cells, treatment
with IL-6 resulted in a rapid and dramatic increase in the
amount of SOCS-1 mRNA already after 0.5 h followed by a
gradual decline over the next 4 h (Fig 2A). The inductive
Figure1
Expression of SOCS-1 transcripts in normal and transformed hu-
man melanocytes in culture as shown by RT-PCR. Total RNA from
NHM and eight human melanoma cell lines was reverse-transcribed
and amplified with SOCS-1 primers. Human PBL stimulated with a-IFN
(1000 U per mL) served as a positive control. Each cDNA sample (lane
1) was analyzed side by side with a contamination control (lane 2)
consisting of total RNA without transcription. The figure depicts one
representative set of three independent experiments with identical
results.
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effect of IL-6 on SOCS-1 mRNA expression was less pro-
nounced in WM9 cells, which are defective in IL-6-mediated
STAT3 activation (Bo¨hm et al, 2001). Accordingly, the re-
sponse of IL-6-mediated SOCS-1 mRNA induction in both
cell lines resembled the kinetics of STAT3-DNA complex
formation after stimulation with IL-6. In WM35 cells, DNA
binding of STAT3 as determined by electric mobility shift
assays was likewise more pronounced and prolonged as
compared with WM9 cells (Bo¨hm et al, 2001). In comparison
with IL-6, the a-IFN-induced upregulation of SOCS-1 mRNA
peaked later and was also less pronounced in WM9 cells
than in WM35 cells (Fig 2B). In summary, these findings
show that SOCS-1 expression can be modulated by ex-
ogenous IL-6 and a-IFN treatment.
SOCS-1 protein expression is suppressed in non-trans-
formed human melanocytes We next investigated the ex-
pression of SOCS-1 at the protein level in NHM and
melanoma cells by western immunoblotting. All tested hu-
man melanoma cell lines expressed SOCS-1 protein which
comigrated with mouse spleen extract used as a positive
control (Fig 3A and B). In contrast, NHM did not express
detectable SOCS-1 protein (Fig 3A). In some experiments,
however, a faint band was detected in NHM upon overex-
posure of the film. To exclude uneven protein loading of the
samples, the SOCS-1 immunoblot was re-probed with an
anti-a-tubulin (Fig 3A). There was no clear-cut relation be-
tween the absolute expression level of SOCS-1 protein and
the state of IL-6 sensitivity. WM9 melanoma cells, however,
which are highly resistant to IL-6 and secrete high amounts
of bioactive IL-6 (Lu and Kerbel, 1993) expressed the
highest amount of SOCS-1 protein. In contrast, WM35 and
A375 melanoma cells (both IL-6 sensitive) expressed less
SOCS-1 protein whereas NHM, which are also sensitive to
IL-6 (Swope et al, 1991), did not express SOCS-1 protein
(Fig 3A).
To further confirm the aberrant SOCS-1 protein expres-
sion in human melanoma cells in vitro, we performed
immunofluorescence studies in one representative cell line.
In WM9 melanoma cells, SOCS-1 immunoreactivity was
detectable as a cytoplasmic granular staining (Fig 4). Re-
placement of the anti-SOCS-1 antibody with the same
amount of negative control rabbit IgG did not produce spe-
cific staining (Fig 4). Conversely, NHM did not stain with the
anti-SOCS-1 antibody (data not shown). Triple staining of
WM9 melanoma cells with the anti-SOCS-1 antibody, an
antibody against the cytoplasmic marker protein disulfide
isomerase (PDI) (Munro and Pelham, 1986; Vaux et al, 1990)
and the nuclear marker 40,6-diamido-2-phenylindole dihy-
drochloride (DAPI) showed significant colocalization be-
tween SOCS-1 and PDI (Fig 4).
SOCS-1 is a progression marker of melanoma in situ To
check if SOCS-1 protein expression is maintained in human
Figure 2
In vitro effect of IL-6 and a-IFN on SOCS-1 mRNA expression in
WM35 (IL-6 sensitive) and WM9 (IL-6 resistant) melanoma cells.
Cells were stimulated with recombinant human IL-6 (10 ng per mL) (A)
or recombinant human a-IFN (1000 U per mL) (B). The relative SOCS-1
mRNA levels were determined in cDNA samples by quantitative real-
time PCR as described in Materials and Methods. The indicated relative
gene expression shows expression levels that were normalized by
GAPDH expression as a standard. Expression levels were determined
independently at three times. Bars represent the mean  SEM. N/A,
unstimulated.
Figure3
Expression of SOCS-1 protein in human melanoma cells and NHM
in vitro. Complete cell lysates derived from cells were normalized for
protein content and subjected to SDS-PAGE (100 mg protein per lane)
followed by western immunoblotting using a polyclonal anti-SOCS-1
antibody (A). To verify equal protein loading of the samples, the original
SOCS-1 blot was stripped and re-probed with an anti-alpha-tubulin
antibody (A). The SOCS-1-related band in melanoma cells comigrated
with a single band in mouse spleen extract used as a positive control
(B). (A) shows a representative blot of several independent experiments
with identical results.
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melanoma cells in situ we examined paraffin-embedded
tissue sections of 56 primary and 11 metastatic melanomas
by immunohistochemistry. SOCS-1 immunoreactivity in situ
was subsequently compared with normal adult skin, 20
congenital and acquired melanocytic nevi as well as five
Spitz nevi, the latter being often difficult to distinguish from
early melanoma.
The demographics of the patients with melanomas is
given in Table I. Specificity of the anti-SOCS-1 antibody
was first established in sections of normal human spleen.
Lymphocytes situated especially within the red pulp
displayed granular cytoplasmic SOCS-1 immunoreactivity
(Fig 5A). Negative controls with polyclonal goat IgG did not
produce any immunostaining (Fig 5B). In accordance with
findings from others (Federici et al, 2002), SOCS-1 immuno-
reactivity was undetectable in the epidermis of normal skin
(Fig 5C). In melanocytes of congenital and acquired me-
lanocytic nevi (including compound and junctional nevi, ne-
void lentigines and Spitz nevi) SOCS-1 immunostaining was
also absent (Fig 5D) (and data not shown). In a number of
nevi, however, epidermal keratinocytes adjacent to the
nevus displayed weak SOCS-1 immunoreactivity (Fig 5D).
Primary cutaneous melanomas expressed a variable de-
gree of SOCS-1 immunoreactivity (Fig 5E, G, I, J ), whereas
metastases were consistently positive (Fig 5K–N ). SOCS-1
immunostaining in the tumor cells of primary and metastatic
melanoma cells was always confined to the cytoplasm.
Negative controls using IgG at the same concentration as
Figure 4
Subcellular localization of SOCS-1 protein in human melanoma
cells in vitro as shown by immunofluorescence. WM9 melanoma
cells were fixed with paraformaldehyde, permeated with Triton X-100,
and triple stained with an anti-SOCS-1 antibody (vs an idiotype control
IgG), an anti-PDI antibody used as a cytoplasmic marker and DAPI as a
nuclear marker. Bound antibodies were detected with secondary an-
tibodies coupled to Texas-red (anti-SOCS-1 and control IgG, red flu-
orescence) and FITC (PDI, green fluorescence). The figure shows a
representative set of several independent experiments with similar re-
sults. Scale bar¼15 mm.
Table I. Patients demographics with melanoma
Characteristic
Number of patients
(total 67)
Mean age years (range) 58.9 (18–91)
Sex
Male 32
Female 35
Site
Head 16
Trunk 28
Limbs 23
Primary tumors 56
Level of invasion (Clark)
Level I 20
Level II 9
Level III 9
Level IV 15
Level V 3
Tumor thickness (mm)a
Tis 20
T1 (o1.0) 18
T2 (1.01–2.0) 5
T3 (2.01–4.0) 8
T4 (44) 5
Melanoma type
SSM 8
LM 7
NM 7
Not classified 34
Metastases 11
Cutaneous 7
mucocutaneous 2
Lymph node 2
aAccording to TNM classification.
SSM, superficial spreading melanoma; LM, lentigo maligna melanoma;
NM, nodular melanoma.
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Figure 5
Expression of SOCS-1 immunoreactivity in melanoma in situ. Deparaffinized sections of normal skin, spleen, melanocytic nevi, and melanomas
were stained with an anti-SOCS-1 polyclonal goat antibody. Bound antibodies were detected using the indirect immunoperoxidase technique.
Normal human spleen (positive control),  200 (A). Negative control of spleen with control IgG at the same concentration as the anti-SOCS-1
antibody,  200 (B). Normal human skin,  200 (C). Absent SOCS-1 immunostaining in melanocytes of an acquired melanocytic compound nevus.
Note weak immunoreactivity in perilesional keratinocytes (),  200 (D). Weak SOCS-1 immunoreactivity in tumor cells of an in situ melanoma,
 400 (E). Negative control of the former,  400 (F). SOCS-1 staining of an early primary cutaneous melanoma, Clark Level II,  200 (G). Negative
control of the former tumor,  200 (H). SOCS-1 immunoreactivity in a primary melanoma, Clark level III; note SOCS-1 immunoreactivity of
keratinocytes in the vicinity of the tumor,  200 (I). Advanced primary melanoma, Clark level IV,  200 (J). Cutaneous metastasis, overview,  100
(K). Higher magnification of the former lesion; note heterogeneous SOCS-1 staining of tumor cells,  200 (L). Lymph node metastasis of a
melanoma, overview,  100 (M). Higher magnification of the former sample,  400 (N).
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the primary antibody did not show any staining (as repre-
sentatively shown in Fig 5F and H). There was no detectable
relationship between SOCS-1 staining intensity/positivity
and the location of the tumor or the morphological type
of melanoma. Similar to nevi, several advanced primary
melanomas and metastases displayed weak SOCS-1
immunoreactivity in perilesional keratinocytes (Fig 5G, I,
J). Interestingly, SOCS-1 immunostaining was accentuated
in the advancing margins of the tumor in a number of met-
astases (Fig 5K ).
For the total group of patients with melanoma, there was
a close relation between SOCS-1 staining intensity/posit-
ivity and tumor progression as classified by tumor invasion
(Clark level), tumor thickness according to Breslow, and
stage of the disease (Figs 6 and 7). Accordingly, the majority
of in situ melanomas (65%) did not express SOCS-1 protein
and those with detectable SOCS-1 immunoreactivity dis-
played only weak staining intensity or positivity. In contrast,
most advanced primary melanomas with a tumor thickness
of 41.0 mm or a Clark level of IV/V were immunoreactive
for SOCS-1 and had a high degree of positivity of 450%
(Figs 6 and 7). The mean SOCS-1 positivity differed signif-
icantly between the different patient groups in relation to the
invasion level according to Clark (po0.0001) (Fig 7). There
was also a significant difference in SOCS-1 positivity of
primary melanomas as a function of vertical growth ac-
cording to Breslow (mean depth of tumors with a positivity
of 450%¼ 2.55 mm versus mean depth of tumors with a
positivity of o50%¼ 0.55 mm; po0.01). Changing the cut-
off value to o25% or o10% to discriminate between low
and high SOCS-1 expression levels did increase the signif-
icance (po0.001). As depicted in Figs 6 and 7 all melanoma
metastases exhibited SOCS-1 immunostaining and this
group exhibited the highest degree of positivity. Collectively,
these findings demonstrate that aberrant SOCS-1 protein
expression is maintained in situ. SOCS-1 is not a specific
melanoma marker but its expression is closely related to
tumor progression.
Discussion
We have shown here that melanoma cells in vitro and in situ
express SOCS-1, a member of the SOCS family, which
downregulates a variety of biological responses to growth
factors and cytokines. SOCS-1 may not be the only mem-
ber of the SOCS family being aberrantly expressed in me-
lanoma. Preliminary studies indicate that additional SOCS
members, particular SOCS-3, are upregulated in trans-
formed melanocytes as well (our own unpublished findings).
Human melanoma does not appear to be the only malig-
nancy exhibiting aberrant SOCS expression. Recently, it
was reported that in breast carcinoma, SOCS-1, -2, -3, and
CIS are also overexpressed (Raccurt et al, 2003).
The initial purpose of the study was to clarify as to
whether SOCS-1 is responsible for the altered response of
melanoma cells to IL-6 (Bo¨hm et al, 2001). By analyzing the
above human melanoma cell lines we could not detect a
clear-cut relation between the absolute level of SOCS-1
protein and the state of IL-6 sensitivity of the examined cell
lines. For example, WM35 melanoma cells, which are highly
sensitive to IL-6, expressed SOCS-1 protein. It is possible,
however, that the relative SOCS-1 protein amount indeed
affects the relative IL-6 sensitivity of a given cell line. There-
fore, it will be interesting to check if melanoma cells with
forced ectopic SOCS-1 protein expression become resist-
ant to IL-6. Further studies will also have to address whether
SOCS-1 expression in melanoma cells in vitro is associated
with resistance to other cytokines, e.g., IFNs. These studies
are currently under investigation in our laboratory.
Of note, SOCS-1 expression in NHM was suppressed at
the protein level although these cells expressed SOCS-1
transcripts as shown by RT-PCR analysis. We have been
unable to detect SOCS-1 protein induction by exogenous
Figure6
SOCS-1 staining intensity varies as a function of tumor thickness
and stage of the disease. SOCS-1 immunoreactivity of tumor cells
within the total number of specimens (n¼67) was assessed semi-
quantitatively by two independent investigators using the following pa-
rameters: absent, weak, strong, and very strong. The percentage of
tumors exhibiting a given staining intensity was subsequently related to
the following categories: melanoma (M) in situ, primary melanoma
(PM)p1 mm, PM41 mm, and melanoma metastases (MM).
Figure7
SOCS-1 staining positivity is linked to the invasion level according
to Clark. Staining positivity of the specimens (n¼67) was assessed by
two independent investigators examining three high-power fields
(  400) and determining the average percentage of SOCS-1 immuno-
reactive tumor cells per sample. Grading of positivity ranged from 1%
to 100% as outlined in Material and Methods. Positivity was subse-
quently related to the invasion level (Clark). Bars represent the SD of
each patient group.
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IL-6 or IFN-a in NHM. Moreover, the amounts of SOCS-1
protein in the examined melanoma cell lines of this study did
not correlate with the levels of endogenously produced IL-6
(our own unpublished findings). These findings suggest
a complex regulation of SOCS protein expression. Pulse-
chase experiments with COS-7 cells transfected with var-
ious SOCS proteins have shown that the half-life of SOCS-1
is only one hour (Siewert et al, 1999). Because of the rapid
turnover of the SOCS proteins, it has been speculated that
the regulation of these proteins occurs primarily at the tran-
scriptional level. It has been reported, however, that SOCS-
1 protein expression is controlled by post-transcriptional
mechanisms. The SOCS box interacts with the elongin BC
complex and binding of the elongin BC complex stabilizes
wild-type SOCS-1 (Kamura et al, 1998). Elongin B and C are
regulatory subunits of the Elongin SIII complex which pos-
itively regulate transcription elongation of RNA polymerase
II (Bradsher et al, 1993a, b; Garrett et al, 1994; Aso et al,
1995). Elongin B is a chaperone-like protein with an 84-
amino-acid amino-terminal ubiquitin-homology domain. El-
ongin B promotes assembly and enhances the stability of
the Elongin SIII complex whereas Elongin C interacts with a
large number of proteins including the Hippel–Lindau (VHL)
tumor suppressor complex (Duan et al, 1995; Garrett et al,
1995; Kibel et al, 1995). Accordingly, in cells from transgenic
mice expressing a mutant form of SOCS-1, F59D-JAB, oc-
cupation of the Elongin BC complex by the mutant reduced
the levels of endogenous SOCS-1 and SOCS-3 and con-
sequently resulted in sustained activation of the JAKs (Ha-
nada et al, 2001). On the other hand, it was reported that
elongin B and C may couple SOCS proteins via the SOCS
box to the proteasomal degradation pathway (Zhang et al,
1999). In addition, two members of the serine/threonine
kinase superfamily, Pim-1 and Pim-2, have recently been
found to regulate the stability and phosphorylation of the
SOCS proteins (Chen et al, 2002). Preliminary have shown
that Pim-2 but not Pim-1 is expressed in a high percentage
of melanoma cell lines but not in normal melanocytes. In-
terestingly, Pim-2 expression correlated with aberrant
SOCS-3 but not with SOCS-1 expression (data not shown).
What could be the function of SOCS-1 being expressed
in human melanoma? As shown by our immunohistochem-
ical studies, the level of SOCS-1 protein expression in situ
correlated well with the tumor stage, level of invasion, and
disease progression. In most in situ melanomas, which have
an excellent prognosis, SOCS-1 immunostaining was ab-
sent. These findings and the accentuated SOCS-1 immuno-
staining of the tumor periphery in some specimens may
suggest an increased invasive potential of tumor cells ex-
pressing SOCS-1. Aberrant expression of SOCS-1 by me-
lanoma cells may either directly promote cell proliferation or
render tumor cells insensitive against IFN released by the
surrounding resident or immune cells. As a consequence of
the latter, SOCS-1 expression by melanoma cells may not
only antagonize the antiproliferative activity of endogenous
IFNs but may also block the upregulating effect of these
cytokines on the expression of class I and II MHC antigen or
intercellular adhesion molecule-1, surface molecules in-
volved in antigen presentation, and tumor cell recognition
(Mortarini et al, 1990; Nistico et al, 1990; Milling et al, 2002).
Moreover, the in vivo response of patients with metastatic
melanomas to exogenously administered IFNs may be af-
fected by melanoma cells expressing SOCS-1. Thus, the
aberrant expression of SOCS-1 by tumor cells may repre-
sent a novel mechanism by which melanoma cells escape
from direct effects of therapeutically applied IFN. Careful
analysis of patients with advanced melanoma responsive
and refractory to immunotherapy with IFN and evaluation of
their in situ expression of SOCS-1 is currently under way in
our laboratory to answer this question. These studies will
clarify if SOCS-1 can be exploited as a predictive or prog-
nostic marker for the in vivo response of IFN given to pa-
tients with metastatic melanoma.
Materials and Methods
Cell culture and stimulation The human melanoma cell lines
WM35, IPC298, WM902B, A375, G361, SK-Mel-30, IGR37, WM9
were routinely cultured in RPMI 1640 (Biochrom, Berlin, Germany)
supplemented with 10% fetal calf serum (FCS), 1% glutamine, and
1% penicillin/streptomycin (all from Biochrom) in a humidified at-
mosphere of 5% CO2. WM35, WM902B, and WM9 cells were a gift
from M. Herlyn (The Wistar Institute, Philadelphia, Pennsylvania).
A375 and G361 cells were purchased from ATCC (Rockville, Mar-
yland), whereas IPC298, IGR37, and SK-Mel-30 cells were ob-
tained from DSMZ (Braunschweig, Germany). In some experiments
melanoma cells were stimulated with 10 ng per mL IL-6 (Upstate,
Lake Placid, New York) or 1000 U per mL a-IFN (R&D Systems,
Wiesbaden, Germany) in RPMI 1640 plus 2% FCS. Normal human
melanocytes were purchased from BioWhittaker (Walkersville,
Maryland) and cultured in MGM3 medium with all supplements
or in absence of artificial supplements, i.e., in MBM2 medium
(BioWhittaker) with 10 nM endthelin-1 (ET-1) (Sigma, Deisenhofen,
Germany) and 40 ng per mL hepatocyte growth factor (HGF) (R&D
Systems). Human peripheral blood lymphocytes (PBL) were iso-
lated from a healthy donor (M.B.) by Ficoll–Hypaque centrifugation
as described previously (Bo¨hm et al, 1994) and were stimulated
with 20 U per mL IL-2 or 1000 U per mL g-IFN for 4 h (both from
R&D Systems).
Preparation of RNA, RT-PCR, and sequencing Total RNA was
isolated from cells using the RNeasy Midi kit from Qiagen (Hilden,
Germany). One microgram of DNA-digested RNA was reverse-
transcribed using oligo(dT) primers and AMV Reverse Transcript-
ase (Promega, Madison, Wisconsin). PCR amplification was per-
formed with REDTaq polymerase (Sigma, Taufkirchen, Germany)
and commercially synthesized primers (Gibco BRL, Gaithersburg,
Maryland). The 1  REDTaq PCR reaction mixture contained 10
mM Tris-HCl (pH 8.3), 50 mM KCl, 1.1 mM MgCl2 and 0.01% gel-
atin, 0.05 U REDTaq DNA polymerase (all from Sigma), 0.2 mM
dNTP mixture (Promega), and 40 pmol of each primer. The human
SOCS-1 primers were as follows: sense primer: 50-TTGCCT
GGAACCATGTGG-30 and antisense primer: 50-GGTCCTGGCCT
CCAGATACAG-30 yielding a 201 bp amplification product. The
amplification program consisted of one cycle at 941C for 6 min,
591C for 2 min, 721C for 1 min, followed by 35 cycles at 941C for 1
min, 591C for 1 min, 721C for 1 min, and a final cycle at 941C for 1
min, 591C for 1 min, 721C for 5 min. cDNA from a-IFN-stimulated
PBL served as a positive control. As a contamination control, orig-
inal RNA from the respective cDNA samples was amplified without
reverse transcription. PCR products were separated electrophore-
tically on 1.5% TAE-agarose gels, stained with ethidium bromide
and photographed under UV. For sequencing, the positive band in
one representative cell line (WM902B) was purified using a gel
extraction kit (Qiagen), cloned into an pGEM-T easy vector (Prome-
ga), and sequenced (4base lab GmbH, Reutlingen, Germany).
Quantitative real-time PCR Quantification of mRNA steady-state
levels of SOCS-1 was carried out by real-time fluorescence
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detection as described before (Mu¨ller et al, 2000). In short, cDNA
was amplified by PCR in the ABI Prism 7700 sequence detector
(PE Biosystems, Foster City, California) with primers and probes
designed by the Primer Express software (PE Biosystems). The
SOCS-1 primers and probe from the coding region of the pub-
lished SOCS-1 gene sequence were as follows. Sense primer:
50-AACTGCTTTTTCGCCCTTAGC-30; antisense primer: 50-CTGAA
AGTGCACGCGGATG-30; probe: 50-AAGATGGCC-TCGGGACCCA
CGA-30. The human GAPDH sense primer was 50-GAAGGTGAA
GGTCGGAGTC-30; the antisense primer was 50-GAAGATGGTGA
TGGGATTTC-30, and the probe was 50-CAACGTTCCCGTTCTCA
GCC-30. The probes were labelled at the 50 end with the dyes FAM
(for the SOCS-1 probe) or VIC (for the GAPDH probe) and at the 30
end with TAMRA which served as a quencher. The 50-to-30 nuc-
lease activity of the Taq polymerase (Applied Biosystems,
Darmstadt, Germany) cleaved the probe and released the fluores-
cent dyes (VIC or FAM), which were detected by the laser detector
of the sequence detector. After the detection threshold was
reached, the fluorescence signal was proportional to the amount
of PCR product generated. The initial template concentration was
calculated from the cycle number when the amount of PCR prod-
uct passed a threshold set in the exponential phase of the PCR.
Relative gene expression levels were calculated using standard
curves generated by serial dilutions of cDNA from IL-2-stimulated
PBL. The relative amounts of gene expression were calculated by
using the expression of GAPDH as an internal standard. At least
three independent analyses were performed for each gene, and
data are presented as the mean  standard error (SEM).
Western immunoblot analysis Total cell lysates were prepared
as outlined previously (Bo¨hm et al, 1995). Protein concentrations
were measured by the Bradford assay (Bio-Rad, Mu¨nchen, Ger-
many). Extracts from mouse spleen (Santa Cruz Biotechnology,
Santa Cruz, California) and total cell lysate from g-IFN-stimulated
PBL served as positive controls. Identical amounts of lysate
proteins were then separated by 4%–12% gradient NuPAGE
(Invitrogen, Carlsbad, California) and blotted to polyvinylidene
difluoride membranes (Bio-Rad). Membranes were blocked over-
night with 10% bovine serum albumin (BSA) (Boehringer, Man-
nheim, Germany) and immunoprobed with a polyclonal antibody
against SOCS-1 (1 mg per mL) (Santa Cruz, H-93). After washing,
membranes were probed with a horseradish peroxidase-conjugat-
ed anti-rabbit IgG antibody (Amersham Life Science, Freiburg,
Germany) and developed using the enhanced chemiluminescence
kit (Amersham Pharmacia Biotech, Uppsala, Sweden). To verify
equal protein loading, the original antibody was stripped from the
membrane by incubation with stripping buffer as described before
(Bo¨hm et al, 1995). Membranes were then reblocked and reprobed
with an anti-a-tubulin antibody (1:1000) (Oncogene Research
Products, San Diego, California).
Immunoﬂuorescence Cells seeded into eight-well tissue cham-
bers (Laboratory-Tek, Nalge Nunc, Naperville, Illinois) were fixed
with 4% paraformaldehyde followed by permeation with 0.3% Tri-
ton X-100 for 10 min at room temperature. Unspecific binding was
blocked with 5% donkey serum for 1h at room temperature. Cells
were then incubated at room temperature for 2 h with an anti-
SOCS-1 antibody (Santa Cruz Biotechnology, H-93) at 1-5 mg per
mL. For double immunostaining, cells were incubated with the anti-
SOCS-1 antibody and a monoclonal antibody against PDI (1:100,
Dianova, Hamburg, Germany). After washing, antigen–antibody
complexes were detected by a donkey anti-rabbit antibody con-
jugated with Texas Red (1:4000, Dianova, Hamburg, Germany) or
by a goat-anti-mouse antibody conjugated to FITC (1:100, Dako,
Hamburg, Germany). After washing, nuclei were finally stained with
DAPI at 100 ng per mL in Tris buffer (pH 7.4) for 1 h at room
temperature. After three washes, slides were mounted in Mowiol
(Hoechst, Frankfurt, Germany). Cells were imaged and examined
with a fluorescence microscope (Leica DMRD/RXA, Wetzlar, Ger-
many). Red fluorescence was excited using the TX2 filter (BP 560/
40 nm) whereas green fluorescence was excited using the FITC
filter (BP 575/30 nm). Emission was measured at 645  75 nm
(Texas Red) and at 635  40 nm (FITC), respectively. For DAPI
staining, an excitation wavelength of 360/40 nm was used. For the
negative controls, rabbit IgG was used at the same concentration
as the primary antibody.
Immunohistochemistry Samples of normal adult human skin
(n¼ 3), of melanocytic nevi (n¼ 20), and cutaneous melanomas
(n¼ 67) from patients undergoing routine surgery for therapeutic or
diagnostic reasons were examined. The melanocytic nevi included
six congenital nevi, four acquired compound nevi, five acquired
junctional nevi, five nevoid lentgines, and five Spitz nevi. Normal
human spleen was used as a positive control. Specimens were
fixed in 7% buffered paraformaldehyde, dehydrated, embedded in
parablast, and mounted on Tissue-Tek (Mikrom, Walldorf, Germa-
ny). Parablast-embedded sections were deparaffinized, micro-
wave-treated for epitope unmasking, quenched for endogenous
peroxidase activity, and blocked with BSA as outlined previously
(Bo¨hm et al, 2002). The sections were incubated overnight with a
goat anti-SOCS-1 antibody (Santa Cruz Biotechnology, N-18) at 1
mg per mL. After washing, sections were developed by an indirect
immunoperoxidase technique using 3-amino-9-ethylcarbazole
(Sigma, Deisenhofen, Germany) as a chromogen. The negative
controls for SOCS-1 were stained with the same amount of goat
IgG instead of the primary antibody. Immunoreactivity of the tumor
cells was scored by two different methods. First, the overall stain-
ing intensity of the tumor cells was assessed as absent, weak,
strong, and very strong. Second, the percentage of stained tumor
cells in each specimen was scored in three high-power fields
(  400) (by M.B. and Z.L.) and the average percentage of tumor
cell staining was calculated. Tumors with 41% of tumor cells
staining were considered positive. Grading of positivity ranged
from 1% to 100%. The relationship between SOCS-1 positivity and
tumor thickness was determined by the Mann–Whitney two-sam-
ple test and the relation between SOCS-1 positivity and Clark level
by ANOVA.
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